Department of Medical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Department of Statistics, Uppsala University, Uppsala, Sweden.
Cytokine. 2023 Sep;169:156269. doi: 10.1016/j.cyto.2023.156269. Epub 2023 Jun 10.
Management of Graves' ophthalmopathy (GO) is still a challenge in Graves' disease (GD). Moreover, 40% of GD patients show radiological muscle enlargement without clinically apparent GO. Delayed treatment of GO may lead to deterioration in prognosis.
Thirty GD patients with overt hyperthyroidism were included in this study, 17 of whom either had GO at diagnosis or developed GO during the study period. Samples were collected at the beginning of the study, at 6 months, and at 24 months. Plasma samples were analyzed for 92 cytokines using the Olink Target 96 inflammation panel.
After adjustment for multiplicity testing using the false discovery rate approach, soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) were significantly elevated in GO patients.
Using a broad cytokine panel we show that patients with Graves' ophthalmopathy have elevated PD-L1 and FGF-23 levels. The findings support previous suggestions that PD-L1 may serve as a treatment target.
格雷夫斯眼病（GO）的治疗仍然是格雷夫斯病（GD）的一个挑战。此外，40%的 GD 患者表现出影像学肌肉肿大而无临床明显的 GO。GO 的延迟治疗可能导致预后恶化。
本研究纳入了 30 名患有明显甲状腺功能亢进的 GD 患者，其中 17 名患者在诊断时或研究期间患有 GO。在研究开始时、6 个月和 24 个月采集样本。使用 Olink Target 96 炎症面板分析血浆样本中的 92 种细胞因子。
经过错误发现率方法调整多重检验后，GO 患者的可溶性程序性死亡配体 1（sPD-L1）和成纤维细胞生长因子 23（FGF-23）显著升高。
使用广泛的细胞因子面板，我们发现患有格雷夫斯眼病的患者 PD-L1 和 FGF-23 水平升高。这些发现支持了 PD-L1 可能作为治疗靶点的先前建议。
